Liquid Biopsies for Lung Cancer: Vision 2020
Liquid biopsies are non-invasive tests, most commonly blood-based, that detect cancer through the identification of shed genetic material into circulation. The technology holds the promise of a non-invasive ‘Swiss army knife’ of diagnostics, with the potential for utility across screening, diagnosis, monitoring, treatment selection, and resistance detection to spare patients unnecessary procedures.
Although liquid biopsies encompass a range of possible targets including circulating tumor DNA (ctDNA), circulating tumor cells and exosomes, ctDNA liquid biopsies have been most swiftly adopted in clinical practice for non-small cell lung cancer.
In this white paper, our CEO and Medical Director, Dr. Min-Han Tan, and our CTO, Dr. Yukti Choudhury, share their expert perspectives on:
Contact us at [email protected] if you have any questions about the white paper.